Immunotherapy Drugs Market to Surpass $580.6 Billion by 2029

 The global Immunotherapy Drugs Market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, registering a robust CAGR of 15.3% during the forecast period. The market is expanding rapidly, driven by technological advancements in antibody engineering, increasing adoption of personalized medicine, and rising demand for targeted cancer therapies.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137717755 

Market Dynamics: Innovation and Personalization Accelerate Adoption

The growing burden of cancer and chronic diseases is significantly boosting demand for immunotherapy drugs worldwide. Advances in monoclonal antibodies, checkpoint inhibitors, and cell-based therapies are transforming treatment paradigms—offering improved efficacy and reduced side effects compared to traditional therapies.

At the same time, increasing investment in R&D and strong clinical pipelines are accelerating innovation. However, stringent regulatory approval processes and the high cost of biologics—particularly monoclonal antibody therapies—remain key challenges for market growth.

Segment Insights: Antibody Drugs Lead Market Expansion

By type, antibody drugs are expected to maintain the largest market share throughout the forecast period. Growth in this segment is driven by rising cancer prevalence, increased adoption of biologics, and supportive government initiatives.

Monoclonal antibodies and checkpoint inhibitors continue to dominate due to their ability to precisely target disease pathways, improving patient outcomes and enabling more personalized treatment strategies.

Application Trends: Cancer Segment Dominates Market Demand

By application, the cancer segment accounted for the largest share and is expected to continue its dominance through 2029. Increasing global cancer incidence, coupled with growing adoption of immunotherapy as a frontline treatment, is fueling demand.

Pharmaceutical companies are intensifying efforts in clinical research, strategic collaborations, and therapy development to enhance immune system responses against tumors—bringing new hope to patients and reshaping oncology care.

Route of Administration: Intravenous Segment Leads and Grows Fastest

The intravenous (IV) route of administration held the largest share in 2023 and is projected to grow at the highest rate during the forecast period.

Its widespread use is attributed to rapid drug delivery, controlled dosing, and consistent therapeutic outcomes—particularly critical in oncology and autoimmune disease treatments.

End-User Insights: Hospitals Drive Market Revenue

By end user, hospitals generated the highest revenue in 2024. Their central role in administering complex therapies, conducting clinical trials, and delivering advanced patient care positions them as key stakeholders in the immunotherapy ecosystem.

Hospitals continue to adopt innovative therapies, supported by their infrastructure, clinical expertise, and focus on improving patient outcomes.

Regional Outlook: North America Maintains Market Leadership

North America is expected to dominate the global immunotherapy drugs market throughout the forecast period. The region benefits from a strong biopharmaceutical industry, high R&D investment, and increasing approval of immunotherapy drugs.

Rising cancer prevalence, expanding clinical trial activity, and rapid adoption of advanced therapies are further strengthening market growth across the region.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=137717755 

Competitive Landscape: Leading Pharma Giants Drive Innovation

The immunotherapy drugs market is highly competitive, with major pharmaceutical companies focusing on innovation, strategic collaborations, and expanding therapeutic pipelines. Key players include: Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland) emerging as top three players in the market. While Pfizer Inc. (US), AstraZeneca (UK), Novartis AG (Switzerland), Amgen Inc. (US), Gilead Sciences, Inc. (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd (Israel), GSK PLC (US), and Abbvie Inc. (US) are some of the other prominent players in the market.

These companies are investing heavily in next-generation immunotherapies, including combination treatments, cell and gene therapies, and novel biologics to strengthen their market positions.

Strategic Outlook: Immunotherapy at the Forefront of Next-Gen Medicine

Immunotherapy is rapidly emerging as a cornerstone of modern medicine, particularly in oncology and chronic disease management. The shift toward precision medicine, targeted therapies, and immune-based treatments is expected to redefine treatment standards globally.

With a strong pipeline, increasing regulatory approvals, and growing clinical adoption, the immunotherapy drugs market is poised for sustained high growth—offering significant opportunities for innovation and improved patient outcomes.

IVD Quality Control Market to Reach $2.15 Billion by 2030, Driven by Rising Lab Accreditation and EQA Demand

 The global In Vitro Diagnostics (IVD) Quality Control Market is projected to grow from USD 1.65 billion in 2025 to USD 2.15 billion by 2030, registering a CAGR of 5.5% during the forecast period. Market growth is being driven by the increasing number of accredited laboratories and the rising demand for external quality assessment (EQA) programs to ensure diagnostic accuracy and compliance.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582 

Market Dynamics: Accreditation and Quality Assurance Drive Adoption

The growing emphasis on laboratory accreditation from global regulatory bodies such as International Organization for Standardization, College of American Pathologists, and Clinical Laboratory Improvement Amendments is significantly boosting demand for robust IVD quality control solutions.

Laboratories are increasingly adopting advanced QC products and participating in EQA programs to ensure testing accuracy, reproducibility, and compliance. This shift is reinforcing the importance of independent quality assessment tools and driving sustained market expansion.

Segment Insights: Third-Party Controls Dominate the Market

By manufacturer type, third-party controls accounted for the largest share of the IVD quality controls market in 2024. Their widespread adoption is attributed to their compatibility across multiple instruments and reagent systems, offering laboratories greater flexibility and cost efficiency.

Unlike OEM controls, third-party solutions provide an independent and unbiased assessment of laboratory performance. Their longer shelf life, stable analyte composition, and clinically relevant ranges make them a preferred choice for laboratories seeking standardization and regulatory compliance.

End-User Trends: Clinical Laboratories to Witness Fastest Growth

By end user, clinical laboratories are expected to register the fastest growth during the forecast period. The increasing volume of diagnostic testing, particularly in specialized and independent labs, is driving demand for high-quality QC solutions.

These laboratories are prioritizing accuracy, reproducibility, and workflow efficiency—leading to increased adoption of multianalyte controls, automated QC systems, and data management solutions. The expansion of high-throughput testing further supports the need for scalable and reliable quality control systems.

Regional Outlook: North America Leads Global Market

North America holds the largest share of the IVD quality controls market, supported by advanced healthcare infrastructure, strong regulatory oversight, and high diagnostic testing volumes.

The region’s leadership is further reinforced by early adoption of automated and molecular diagnostic technologies, as well as a strong presence of leading industry players. Continuous investments in innovation and stringent quality standards ensure sustained demand for advanced QC solutions.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=198032582 

Competitive Landscape: Focus on Innovation and Compliance

The IVD quality controls market is highly competitive, with leading players focusing on expanding product portfolios, enhancing QC accuracy, and supporting regulatory compliance. Key companies include:  Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific, Inc. (US), Randox Laboratories Ltd. (UK), LGC Limited (UK), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (US), Danaher Corporation (US), Sysmex Corporation (Japan), Bio-Techne Corporation (US), Microbix Biosystems Inc. (Canada), Microbiologics, Inc. (US), ZeptoMetrix (US), Fortress Diagnostics (UK), Helena Laboratories Corporation (US), Streck, Inc. (US), SERO AS (Norway), Maine Molecular Quality Controls, Inc. (US), Sun Diagnostics, LLC (US), Alpha-Tec (US), Grifols, S.A. (Spain), ConeBioproducts (US), Eurotrol B.V. (Netherlands), and Biorex Diagnostics (UK).

These companies are investing in advanced QC materials, digital quality management systems, and global distribution capabilities to meet the evolving needs of diagnostic laboratories.

Strategic Outlook: Quality Control as a Cornerstone of Diagnostic Excellence

As diagnostic testing becomes more complex and high-throughput, quality control is emerging as a critical pillar of laboratory operations. The shift toward automation, molecular diagnostics, and point-of-care testing is further increasing the need for reliable and scalable QC solutions.

Going forward, innovation in multianalyte controls, data integration, and real-time monitoring will shape the future of the market—ensuring improved diagnostic accuracy, regulatory compliance, and patient outcomes.

Biobanking Market to Reach $11.82 Billion by 2030

 The global Biobanking Market is projected to grow from USD 7.65 billion in 2025 to USD 11.82 billion by 2030, registering a CAGR of 9.1% during the forecast period. Market expansion is being driven by the increasing focus on precision medicine, a rapidly growing cell and gene therapy pipeline, and advancements in automated sample handling and storage technologies.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=594 

Market Dynamics: Precision Medicine and Automation Reshape Biobanking

Biobanking is becoming a critical backbone of modern healthcare and life sciences research. The growing demand for personalized therapies and biologics is significantly increasing the need for high-quality biological sample storage and management.

End-to-end automation is transforming biobank operations—improving efficiency, reducing human error, and ensuring consistent sample integrity. At the same time, sustainability initiatives and green-lab solutions are emerging as key opportunities for innovation. However, long-term funding stability, particularly for public biobanks, remains a challenge for market stakeholders.

Product Insights: Equipment Segment Leads with Critical Storage Infrastructure

By product, the equipment segment accounted for the largest share of the biobanking market in 2024. Core infrastructure such as freezers, refrigerators, and cryogenic storage systems plays a vital role in preserving biological samples including blood, tissues, and DNA.

Ultra-low temperature freezers and cryogenic systems are especially critical for maintaining the viability of sensitive materials such as stem cells, cell lines, and nucleic acids over extended periods—making them indispensable in research, diagnostics, and therapeutic development workflows.

End-User Trends: Pharma, Biotech & CROs to Drive Fastest Growth

The pharmaceutical & biotechnology companies and contract research organizations (CROs) segment is expected to register the highest growth rate during the forecast period.

This growth is fueled by increasing demand for biologics, biosimilars, and advanced therapies such as cell and gene therapies. These organizations rely heavily on biobanking services for clinical sample management, drug development, and large-scale research—driving adoption of advanced storage and data management solutions.

Regional Outlook: Asia Pacific Emerges as High-Growth Market

The Asia Pacific region is projected to register the highest CAGR during the forecast period. Countries such as China, India, and Japan are rapidly expanding their research infrastructure and healthcare capabilities.

Biobanks in the region are becoming essential for supporting drug discovery, clinical trials, and population health studies. Additionally, rising chronic disease prevalence and aging populations are increasing demand for comprehensive biobanking solutions to enable future healthcare innovations.

Sepak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=594 

Competitive Landscape: Innovation and Global Expansion Intensify Competition

The biobanking market is characterized by strong competition and continuous innovation, with leading players focusing on automation, advanced storage technologies, and integrated solutions. Key companies include: The key players in the biobanking market include Thermo Fisher Scientific Inc. (US), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (BD) (US), Qiagen (Germany), Merck KGaA (Germany), Labcorp (US), Eurofins Scientific (Luxembourg), and Cryoport (US), among other players.

These companies are investing in scalable, automated, and sustainable biobanking solutions to meet the growing global demand for high-quality biological sample management.

Strategic Outlook: Biobanking at the Core of Next-Generation Healthcare

As life sciences shift toward precision medicine, regenerative therapies, and data-driven research, biobanking is becoming increasingly central to innovation.

Future growth will be shaped by advancements in automation, integration with digital platforms, and sustainable lab practices. Organizations that can deliver scalable, compliant, and high-integrity biobanking solutions will be well-positioned to capitalize on this expanding market.

Global Infusion Pump Market Expected to Grow to $28.3 Billion by 2030

 The report "Infusion Pump Market by Product (Accessories (Dedicated, Non-dedicated), Devices (Insulin, Syringe, Volumetric, Enteral, PCA Pump)), Technology (Traditional, Specialty), Mode (Stationary, Portable), Application (Cancer, Diabetes) - Global Forecast to 2030", is projected to reach USD 28.3 billion by 2030 from USD 19.9 billion in 2025, growing at a CAGR of 7.4%.

 
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=90374506
 
Browse

• 608   Market Data Tables
• 86     Figures
• 582   Pages and in-depth TOC on " Infusion Pump Market - Global Forecast to 2030”

Some of the prominent key players are:

• Becton, Dickinson and Company (US),
• Baxter International Inc. (US),
• B. Braun Melsungen AG (Germany),
• Terumo Corporation (Japan),
• NIPRO (Japan),
• Fresenius Kabi (Germany), 
• ICU Medical, Inc. (US). and many more.......

 

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Infusion Pump Market.

Get Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=90374506

• Based on products, The devices segment of the infusion pump market held the largest share in 2024 because infusion pumps are widely used in hospitals, clinics, and homecare for precise and controlled drug delivery. The rise in chronic diseases, more surgical procedures, and the increasing adoption of advanced, smart, and portable pumps have further boosted demand.
• Based on type, the accessories & consumables segment accounted for a larger market share in 2024. The substantial market share attributed to infusion pump disposables is primarily linked to their critical role in ensuring safe and effective medication administration through recurrent use. This category encompasses essential components such as infusion sets, catheters, tubing, and connectors, all of which are single-use items that require regular replacement to maintain patient safety and minimize infection risk.
• Based on applications, The rapid expansion of the diabetes management segment is primarily driven by the increasing prevalence of diabetes, alongside significant technological advancements in infusion pump devices, notably insulin pumps. A key factor propelling this segment forward is the emergence of sophisticated insulin delivery systems, specifically hybrid closed-loop systems, commonly referred to as artificial pancreas devices.
• Geographically, the infusion pumps market is segmented into North America, Europe, APAC, Latin America, and the Middle East & Africa. In 2024, North America emerged as the dominant player in the infusion pump market, primarily driven by substantial healthcare expenditures in the US.

Infusion pumps are medical devices used to deliver controlled amounts of fluids, such as nutrients and medications, into a patient’s body. The market growth is driven by the rising prevalence of chronic diseases such as diabetes and cancer, increasing demand for advanced drug delivery systems, and growing adoption of ambulatory and homecare settings. Furthermore, technological advancements in smart infusion systems and supportive regulatory frameworks promoting patient safety are expected to boost market expansion during the forecast period.

 

The market is expected to experience significant growth over the next decade, driven by increasing healthcare demands, technological progress, and the rising need for precise drug delivery systems. Infusion pumps are being adopted more widely because of their ability to deliver controlled and accurate doses, making them essential for managing chronic diseases, oncology treatments, and pain management. The move toward home healthcare, along with the integration of smart, connected pump technologies, further boosts their importance in enhancing patient safety and treatment results. With a growing global patient population and a focus on advanced care solutions, infusion pumps are poised to play a key role in modern healthcare delivery.

Growing Eye Care Needs Propel Optometry Equipment Market to $6.1 Billion by 2029

The report "Optometry Equipment Market by Type (OCT, Ophthalmoscope, Autorefractor, Tonometer, Slitlamp, Wavefront Analyzer), Application (General Examination, Cataract, Glaucoma,), End User (Eye Clinics, Hospitals), and Region - Global Forecast to 2029", is valued at an estimated USD 4.5 billion in 2024 and is projected to reach USD 6.1 billion by 2029, at a CAGR of 6.4% during theK forecast period.

 
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=14475790
 
Browse

• 321      Market Data Tables
• 43        Figures
• 290      Pages and in-depth TOC on "Optometry Equipment Market - Global Forecast to 2029”.

Some of the prominent key players are:

• Carl Zeiss Meditec AG (Germany),
• EssilorLuxottica (France),
• Alcon (Switzerland),
• Topcon Corporation (Japan),
• Bausch Health Companies Inc. (Canada), and many more......

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Optometry Equipment Market.

 

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=14475790

• According to product type, the worldwide optometry equipment market is divided into three segments: goods for general examinations, cornea and cataract examinations, and products for glaucoma and retinal examinations. In2023, the optometry equipment market was dominated by the sector that produced examination goods for glaucoma and retina.
• The market for optometry equipment is divided into segments based on applications, including age-related macular degeneration, cataract surgery, glaucoma, and general exams. As of 2023, the worldwide optometry equipment market was dominated by the general examination segment.
• By end user, the optometry equipment market is divided into eye clinics, hospitals, and other consumers. The sector that held the biggest share of the global optometry equipment market in 2023 was clinics.
• There are five main regions that make up the global market for optometry equipment: North America, Europe, Asia Pacific, and Rest of the World (which includes Latin America, the Middle East & Africa, and GCC countries). In terms of market share, North America led the optometry equipment market in 2023.

The principal drivers propelling the expansion of this market are the growing prevalence of eye illnesses, advancements in ophthalmic device technology, expanding government initiatives aimed at preventing visual impairment, growing healthcare expenses, and rising disposable incomes. Companies in the market for optometry equipment are finding that developing nations like China, Japan, and India provide attractive opportunities.

Digital Pathology Market to Reach $2.75 Billion by 2030

 The global Digital Pathology Market is projected to grow from USD 1.46 billion in 2025 to USD 2.75 billion by 2030, at a CAGR of 13.5% during the forecast period. Growth is being fueled by the increasing demand for remote pathology solutions, rapid adoption of AI-based image analysis, and the need for faster, more accurate diagnostic outcomes.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=844 

Market Dynamics: AI, Cloud, and Remote Collaboration Transform Pathology

The shift toward digital healthcare is accelerating the adoption of digital pathology solutions across hospitals, laboratories, and research institutions. Technologies such as whole-slide imaging and cloud-based platforms are enabling pathologists to collaborate remotely, significantly improving diagnostic efficiency and reducing turnaround times.

Integration with laboratory information systems (LIS) and the growing emphasis on precision medicine are further enhancing the value proposition of digital pathology. These solutions allow for seamless data sharing, improved workflow automation, and advanced image analytics.

Segment Insights: Human Pathology Drives Rapid Growth

By type, the human pathology segment is expected to register the fastest growth during the forecast period. The increasing prevalence of chronic diseases, particularly cancer, is driving demand for accurate and efficient diagnostic tools.

Digital pathology offers several advantages over traditional methods, including improved image analysis, reduced physical storage requirements, and faster retrieval and sharing of pathology slides for second opinions—making it a critical tool in modern clinical diagnostics.

End-User Trends: Pharma & Biotech Companies Lead Adoption

By end user, pharmaceutical and biotechnology companies accounted for the largest share of the market in 2024. The growing use of digital pathology in drug discovery, development, and personalized medicine is a key driver for this segment.

These organizations leverage high-resolution imaging and automated analysis to accelerate tissue evaluation, enable high-throughput screening, and identify potential drug candidates more efficiently—significantly reducing time-to-market for new therapies.

Regional Outlook: North America Maintains Market Leadership

North America dominated the global digital pathology market in 2024, supported by strong investments in healthcare technologies, advanced infrastructure, and a high prevalence of chronic diseases such as cancer.

The region also benefits from a strong presence of research institutions and leading technology providers, fostering continuous innovation and widespread adoption of digital pathology solutions.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=844 

Competitive Landscape: Innovation and AI Integration Drive Market Competition

The digital pathology market is highly competitive, with key players focusing on AI integration, cloud capabilities, and strategic collaborations. Prominent companies include: Prominent players in the digital pathology market include Huron Digital Pathology (Canada), Hologic, Inc. (US), Corista (US), Indica Labs Inc. (US), 3DHISTECH (Hungary), Objective Pathology Services Limited (Canada), OptraSCAN (US), Sectra AB (Sweden), Akoya Biosciences, Inc. (US), Hamamatsu Photonics K.K. (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Proscia Inc. (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Glencoe Software, Inc. (US), Aiforia (Finland), Paige AI, Inc. (US), Fujifilm Holdings Corporation (Japan), Danaher Corporation (US), Koninklijke Philips N.V. (Netherlands), Mikroscan Technologies, Inc. (US), PathAI (US), Motic Digital Pathology (US), and Kanteron Systems (Spain).

These companies are investing heavily in AI-driven diagnostic tools, scalable cloud platforms, and integrated solutions to enhance diagnostic accuracy and workflow efficiency.

Strategic Outlook: Digital Pathology at the Core of Precision Diagnostics

As healthcare systems move toward data-driven and precision medicine approaches, digital pathology is becoming a foundational technology in diagnostics and research.

The convergence of AI, cloud computing, and high-resolution imaging is expected to redefine pathology workflows—enabling faster diagnoses, improved collaboration, and better patient outcomes. Moving forward, innovation, interoperability, and scalability will remain key priorities for stakeholders in this rapidly evolving market.

AMD Drugs Market: Driven by Innovation in Retinal Therapies

 The global Age-related Macular Degeneration (AMD) Drugs Market is projected to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, registering a CAGR of 10.7% during the forecast period. The market is witnessing robust growth fueled by rising prevalence of AMD, increasing geriatric population, and rapid advancements in retinal drug development.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37446234 

Market Dynamics: Aging Population and Innovation Fuel Demand

The increasing global burden of age-related vision disorders is a major factor driving the AMD drugs market. Lifestyle changes, dietary habits, and longer life expectancy are contributing to a higher incidence of AMD worldwide.

A strong pipeline of novel therapies—many receiving fast-track designations—is accelerating drug approvals and expanding treatment options. Additionally, improved reimbursement frameworks are enhancing patient access and affordability, further supporting market growth.

Emerging markets across Asia Pacific and Latin America are also creating new growth opportunities, while pharmaceutical companies continue to explore next-generation drug modalities to improve treatment efficacy and reduce dosing frequency.

Product Insights: Eylea Maintains Market Leadership

By product, Eylea & Eylea HD accounted for the largest share of the AMD drugs market in 2023. Their widespread adoption is driven by strong clinical efficacy and broad indications, including treatment for retinal vein occlusion (RVO) and diabetic macular edema.

However, increasing competition from newer therapies such as Vabysmo, which offers reduced dosing frequency, is gradually reshaping prescribing patterns and improving patient compliance.

Other key therapies include Lucentis and Syfovre, contributing to a dynamic and competitive product landscape.

Disease Insights: Wet AMD Dominates Treatment Demand

By disease type, wet AMD accounted for the largest share of the market in 2023, driven by its higher severity and the availability of multiple targeted therapies.

The condition affects millions globally and is strongly associated with aging populations. According to projections from the World Health Organization, the number of individuals aged 60 and above is expected to double by 2050—significantly increasing the patient pool for AMD treatments.

Ongoing research by emerging companies such as Stealth BioTherapeutics Inc., Ocular Therapeutix, Inc., and Opthea Limited is further advancing novel treatment approaches for wet AMD.

Regional Outlook: North America Leads Global Market

North America accounted for the largest share of the AMD drugs market in 2023, driven by a high prevalence of AMD, strong healthcare spending, and rapid adoption of advanced therapies.

The region benefits from a well-established pharmaceutical ecosystem, robust clinical trial activity, and continuous drug approvals. The presence of leading drug manufacturers and research institutions further strengthens its market position.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=37446234 

Competitive Landscape: Strong Pipeline and Strategic Expansion Drive Competition

The AMD drugs market is highly competitive, with leading pharmaceutical companies focusing on innovation, biologics development, and biosimilar expansion. Key players include:Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals (US), Coherus BioSciences (US), Astellas Pharma Inc. (Japan), Biogen (US), STADA Arzneimittel AG  (Germany), Formycon AG (Germany), Biocon. (India), Outlook Therapeutics, Inc. (US), Intas Pharmaceuticals Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Chengdu Kanghong Biotech Company (China), and Sandoz Group AG (Switzerland).

These companies are investing heavily in next-generation biologics, extended-duration therapies, and biosimilars to improve patient outcomes and expand market reach.

Strategic Outlook: Toward Long-Acting and Patient-Centric Therapies

As the AMD treatment landscape evolves, the focus is shifting toward long-acting therapies, reduced dosing frequency, and personalized treatment approaches.

Advancements in biologics and combination therapies are expected to redefine treatment standards, improving patient adherence and clinical outcomes. With a strong pipeline and increasing global awareness of eye health, the AMD drugs market is poised for sustained high growth in the coming years.

HLA Typing for Transplant Market : Rising Organ Transplants and Molecular Innovations

 The global HLA Typing for Transplant Market is projected to grow from USD 1.1 billion in 2025 to USD 1.4 billion by 2030, at a CAGR of 6.0% during the forecast period. Market expansion is being driven by the rising volume of organ transplantation procedures, advancements in molecular diagnostic technologies, and increasing investments in transplant research and infrastructure.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96374742 

Market Dynamics: Rising Transplant Demand and Precision Diagnostics Fuel Growth

The growing global demand for organ transplants is a primary factor driving the adoption of HLA typing solutions. Accurate donor-recipient matching is critical to reducing transplant rejection rates and improving patient outcomes, making HLA typing an essential component of modern transplantation practices.

Technological advancements—particularly in next-generation sequencing (NGS) and polymerase chain reaction (PCR)—are significantly enhancing the precision and speed of HLA typing. In addition, supportive government initiatives and increased funding for genomics research are accelerating innovation and expanding access to advanced diagnostic solutions.

Industry players are also focusing on strengthening manufacturing capabilities and distribution networks, especially in emerging markets, further contributing to market growth.

Segment Insights: Reagents & Consumables Lead Market Demand

By product & service, the reagents & consumables segment accounted for the largest share of the market in 2024. This dominance is driven by the growing need for accurate and rapid identification of HLA alleles during transplantation procedures.

The increasing emphasis on minimizing transplant rejection and improving clinical outcomes has elevated the importance of high-quality reagents and consumables. Continuous advancements in molecular biology techniques are expected to further enhance the efficiency and reliability of these products, supporting sustained segment growth.

Technology Trends: Molecular Assays Dominate HLA Typing

By technology, the molecular assays segment held the largest market share in 2024. Techniques such as NGS and PCR are widely adopted due to their superior resolution and accuracy compared to traditional serological methods.

These technologies enable precise donor-recipient matching, which is critical for successful transplantation outcomes. As healthcare providers increasingly adopt advanced molecular diagnostics, this segment is expected to remain a key driver of market growth.

End-User Insights: Reference Laboratories Lead with High Throughput Expertise

By end user, independent reference laboratories accounted for the largest share of the market in 2024. Their ability to handle high sample volumes efficiently, combined with specialized expertise in complex HLA testing, positions them as key contributors to the transplantation ecosystem.

These laboratories play a crucial role in delivering accurate and timely results, supporting transplant centers and hospitals in making informed clinical decisions.

Regional Outlook: North America Leads, Asia Pacific Emerges as Growth Engine

North America dominated the HLA typing for transplant market in 2024, driven by a high volume of organ transplant procedures, strong presence of leading diagnostic companies, and robust research collaborations.

Meanwhile, the Asia Pacific region is expected to witness the fastest growth during the forecast period, supported by expanding healthcare infrastructure, increasing awareness of transplant diagnostics, and rising investments in genomic technologies.

Sepak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=96374742 

Competitive Landscape: Innovation and Strategic Expansion Shape Market Leadership

The HLA typing market is characterized by strong competition and continuous technological innovation. Key players include: Thermo Fisher Scientific  (US), Illumina, Inc. (US), QIAGEN (Germany),  CareDx, Inc.  (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Immucor, Inc. (US),  Werfen (US), TBG Biotechnology Corporation (Taiwan), Fujirebio (Japan), Omixon Inc. (US), GenDX (Netherlands), BAG Diagnostics GmbH (Germany), Creative Biolabs (US), and PacBio (US)

These companies are focusing on advanced sequencing technologies, product innovation, and strategic collaborations to strengthen their market presence and address the growing demand for precision transplant diagnostics.

Strategic Outlook: Precision Matching to Define the Future of Transplantation

As the global healthcare ecosystem increasingly prioritizes precision medicine and improved transplant outcomes, HLA typing technologies are becoming indispensable.

The continued evolution of molecular diagnostics, coupled with expanding transplant programs and growing investments in genomics, is expected to drive sustained market growth. Going forward, innovation, scalability, and accessibility will be key factors shaping the future of HLA typing for transplantation.

Clinical Decision Support Systems Market to Reach $3.89 Billion by 2030

 The global Clinical Decision Support Systems (CDSS) Market is projected to grow from USD 2.46 billion in 2025 to USD 3.89 billion by 2030, registering a CAGR of 9.6% during the forecast period. Growth is being driven by rapid digital transformation across healthcare systems, increasing reliance on data-driven clinical decisions, and the integration of advanced technologies such as artificial intelligence (AI) and machine learning (ML).

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=18085342 

Market Dynamics: AI and Digital Health Ecosystems Reshape Clinical Decision-Making

The adoption of electronic health records (EHRs) and healthcare IT infrastructure continues to be a primary catalyst for CDSS growth. These systems enable seamless integration of decision support tools into clinical workflows, allowing providers to access real-time, evidence-based insights.

Rising prevalence of chronic diseases and the shift toward personalized healthcare are further accelerating adoption. CDSS platforms empower clinicians to develop tailored treatment plans while improving diagnostic accuracy and care outcomes.

Technological advancements in AI, natural language processing (NLP), and predictive analytics are transforming CDSS capabilities—enabling faster data interpretation, reducing medical errors, and enhancing operational efficiency across healthcare organizations.

Segment Insights: On-Premise Dominance, Active CDSS Drives Future Growth

By delivery mode, on-premise CDSS solutions accounted for the largest market share in 2024. Healthcare institutions—particularly large hospitals—continue to prioritize data security, system control, and customization capabilities, all of which are key advantages of on-premise deployments.

These systems allow organizations to safeguard sensitive patient data within internal infrastructures while ensuring seamless integration with existing workflows.

By interactivity level, the active CDSS segment is expected to witness the fastest growth during the forecast period. Active CDSS solutions provide real-time alerts, reminders, and clinical recommendations directly within physician workflows, significantly enhancing clinical efficiency and patient safety.

Government initiatives promoting healthcare IT adoption—including policies from the U.S. Department of Health and Human Services—are further accelerating the uptake of active CDSS solutions.

Regional Outlook: Asia Pacific Emerges as a Strategic Growth Hub

The Asia Pacific region is expected to register significant growth during the forecast period, driven by rising healthcare investments, expanding digital infrastructure, and increasing awareness of health IT solutions.

Government-led initiatives such as India’s digital health programs and China’s healthcare IT reforms are accelerating the adoption of EHRs and CDSS platforms. Rapid urbanization and a growing burden of chronic diseases are further driving demand for advanced clinical technologies to improve healthcare delivery and outcomes.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=18085342 

Competitive Landscape: Innovation and Strategic Expansion Intensify Market Competition

The CDSS market is highly dynamic, with leading players focusing on innovation, partnerships, and global expansion strategies. Key companies include: Wolters Kluwer N.V. (Netherlands), Oracle (US), Merative (US), Change Healthcare (US), Veradigm Inc. (US), athenahealth (US), Epic Systems Corporation (US), Elsevier B.V. (Netherlands), Zynx Health (US), Koninklijke Philips N.V. (Netherlands), Medical Information Technology, Inc. (US), NextGen Healthcare, Inc. (US), CureMD Healthcare (US), Siemens Healthineers (Germany), EBSCO Information Services (US), GE HealthCare (US), eClinicalWorks (US), The Medical Algorithms Company (UK), RAMPmedical (Germany), Hera-MI (France), CareCloud, Inc. (US), VisualDx (US), Premier, Inc. (US), First Databank, Inc. (US), and Strata Decision Technology (US) are the major players in this market. 

These organizations are actively investing in AI-enabled platforms, interoperability solutions, and cloud capabilities to strengthen their competitive positioning and address evolving healthcare demands.

Strategic Outlook: CDSS as a Core Pillar of Intelligent Healthcare

As healthcare systems transition toward value-based, data-driven care models, CDSS platforms are becoming indispensable tools for clinicians and healthcare providers.

The convergence of AI, real-time analytics, and integrated health IT ecosystems is expected to redefine clinical workflows—enabling faster, more accurate decision-making and improved patient outcomes. Moving forward, scalability, interoperability, and intelligent automation will remain central to CDSS innovation strategies.

Molecular Diagnostics Industry Set for Robust Growth, Valued at $30.74 Billion by 2030

 According to MarketsandMarkets™, The report "Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), and Application (Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)) - Global Forecast to 2030", is valued at an estimated USD 19.48 billion in 2025 and is projected to reach USD 30.74 billion by 2030 at a CAGR of 9.6% during the forecast period.

 
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=833
 
Browse

• 772     Market Data Tables
• 61       Figures
• 539     Pages and in-depth TOC on " Molecular Diagnostics Market - Global Forecast to 2030”.

 

Some of the prominent key players are:

• Danaher Corporation (US),
• F. Hoffmann-La Roche Ltd. (Switzerland),
• Hologic, Inc. (US),
• Illumina, Inc. (US),
• Abbott (US),
• bioMérieux (France),
• Thermo Fisher Scientific Inc. (US),
• QIAGEN N.V. (Netherlands),
• Revvity, Inc. (US),and many more......

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Molecular Diagnostics Market.

Get Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=833

• By Product & Service, The global molecular diagnostics market is segmented into reagents & kits, instruments, and services & software. The reagents & kits segment represented the largest segment of the molecular diagnostics market, primarily because these products are consumables that are required in high volumes for each diagnostic test, ensuring recurring demand.
• By test type, the molecular diagnostics market is divided into lab tests and PoC tests. The lab tests segment accounted for the largest market in 2024. This is primarily due to the widespread use of molecular testing in centralized laboratories, which handle high patient volumes and require advanced, high-throughput platforms.
• By sample type, the molecular diagnostics market is segmented into blood, serum & plasma; urine; and other samples. The blood, serum, and plasma segment is projected to be the fastest-growing market during the forecast period. This growth is driven by the broad clinical applicability of these samples in detecting infectious diseases, genetic disorders, and cancer.
• By Technology, the molecular diagnostics market is categorized into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies.
• Based on applications, the molecular diagnostics market is segmented into infectious disease diagnostics, oncology testing, genetic testing, and other applications. Among these, the infectious disease diagnostics segment holds the largest share.
• By end user, the molecular diagnostics is categorized into diagnostic laboratories, hospitals & clinics, and other end users. The diagnostic laboratories segment accounted for the largest market.
• The molecular diagnostics market has been segmented into five geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is estimated to be the largest regional market for molecular diagnostics, supported by a strong healthcare infrastructure and high adoption of advanced testing technologies.

The molecular diagnostics market is experiencing significant growth, driven by a combination of technological advancements and rising healthcare needs. The increasing prevalence of infectious diseases, cancer, and genetic disorders is further fueling the demand for accurate and early diagnostic solutions. Technological innovations in PCR, next-generation sequencing (NGS), and isothermal amplification have enhanced test speed, sensitivity, and versatility, supporting broader clinical adoption. Additionally, expanding access to healthcare in emerging markets, increasing investment in research and development, and rising awareness of preventive health are further contributing to market expansion.